Loading...
•
Mar 31, 2022
Nektar Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022.
Key Takeaways
Nektar Therapeutics reported revenue of $24.8 million and a net loss of $90.4 million for the first quarter of 2022. The company's cash and investments in marketable securities were approximately $704.4 million as of March 31, 2022, expected to support operations into 2025. A new strategic plan refocuses the company around specific investment into its most important pipeline programs.
Revenue for Q1 2022 was $24.8 million, compared to $23.6 million in Q1 2021.
Net loss for Q1 2022 was $90.4 million, or $0.49 loss per share, compared to a net loss of $123.0 million, or $0.68 loss per share in Q1 2021.
Total operating costs and expenses in Q1 2022 were $141.4 million, compared to $133.0 million in Q1 2021.
Cash and investments in marketable securities were approximately $704.4 million as of March 31, 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...